Gonadotropins: a cohesive gender-based etiology of Alzheimer disease.

Abstract

While there is ample experimental evidence supporting the role of estrogen in the pathogenesis of Alzheimer disease, recent inconclusive data regarding hormone replacement therapy (HRT), specifically, the unexpected results of the Women's Health Initiative (WHI) Memory Study has raised serious questions regarding the protective effects of estrogen. Because of this and other inconsistencies in the estrogen hypothesis, we propose that another hormone of the hypothalamic-pituitary-gonadal axis, luteinizing hormone, is a major factor in the pathogenesis of Alzheimer disease. Specifically, we suspect that the increase in gonadotropin concentrations, and not the decrease in steroid hormone (e.g., estrogen) production following menopause/andropause, is a primary causative factor for the development of Alzheimer disease. In this review, we examine how the gonadotropins may play a central and determining role in modulating the susceptibility to, and progression of, Alzheimer disease.

• Authors: Kate M Webber, Gemma Casadesus, Craig S Atwood, Richard L Bowen, George Perry, Mark A Smith
• Journal: Molecular and cellular endocrinology (Mol Cell Endocrinol) Vol. 260-262 Pg. 271-5 (Jan 02 2007) ISSN: 0303-7207 [Print] Ireland
• PMID: 17052835 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Gonadotropins
• Gonadotropin-Releasing Hormone

Topics

• Alzheimer Disease (etiology, therapy)
• Gonadotropin-Releasing Hormone (antagonists & inhibitors)
• Gonadotropins (metabolism)
• Gonads (pathology)
• Humans
• Hypothalamus (pathology)
• Pituitary Gland (pathology)
• Sex Characteristics